BCIQ Profiles

Company Profile ReportTarget Profile Report

Tethering bleeding risk

Tetherex’s antithrombotic therapy could reduce or eliminate risks of bleeding

With a mechanism that blocks thrombosis-contributing cells but not coagulation, Tetherex Pharmaceuticals Inc.’s pan-selectin inhibitor SelK2 could treat venous thromboembolism with little to no risk of bleeding.

Chairman and CEO Scott Rollins said while antithrombotic drugs including generic heparin, warfarin and approved Factor Xa inhibitors “do a good job of stopping thrombosis,” they carry risks of bleeding because they block the coagulation system. There are nine marketed

Read the full 662 word article

How to gain access

Continue reading with a
two-week free trial.